Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119472 | 1.00 | MDM4 (0.53) | MDM4TP53PPARGPPARACASP3 | |
| SCHEMBL29398558 | 1.00 | MDM4 (0.53) | MDM4TP53PPARGPPARACASP3 | |
| SCHEMBL29402444 | 1.00 | MDM4 (0.53) | MDM4TP53PPARGPPARACASP3 | |
| SCHEMBL10622470 | 1.00 | MDM4 (0.53) | MDM4TP53PPARGPPARACASP3 | |
| Water SCHEMBL5158697 | 0.99 | MDM4 (0.52) | MDM4TP53PPARGPPARACASP3 | |
| SCHEMBL8415223 | 0.95 | MDM4 (0.51) | MDM4TP53PPARGPPARACASP3 | |
| SCHEMBL7316241 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL1228254 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL118169 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119455 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | claimed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | claimed |
| US-11891655-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | BATTELLE MEMORIAL INSTITUTE (US) | 2024-02-06 | — | — | US | disclosed |
| EP-3692014-B1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | BATTELLE MEMORIAL INSTITUTE (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-111433176-B | Probes for selectively characterizing enzymes involved in xenobiotic metabolism and methods of making and using the same | 巴特尔纪念研究院 | 2023-08-29 | — | — | CN | disclosed |
| CN-112279888-B | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-09-13 | — | — | CN | disclosed |
| US-20220282317-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | BATTELLE MEMORIAL INSTITUTE (US) | 2022-09-08 | — | — | US | disclosed |
| CN-112209991-B | Tripeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2022-08-12 | — | — | CN | disclosed |
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | BATTELLE MEMORIAL INSTITUTE (US) | 2022-05-31 | — | — | US | disclosed |
| CN-112279888-A | Polypeptide inhibitor of APC/Asef interaction and application thereof | 上海交通大学医学院 | 2021-01-29 | — | — | CN | disclosed |
| EP-3692014-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | Battelle Memorial Institute (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-1487493-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | The Administrators of The Tulane Educational Fund (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1402271-A2 | BENZOPHENONE-LINKED CRF AND CRF-LIKE PEPTIDES FOR COVALENT LABELING OF CORTICOTROPIN-RELEASING FACTOR (CRF) BINDING PROTEIN | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003074551-A2 | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2002095395-A2 | BENZOPHENONE-LINKED CRF AND CRF-LIKE PEPTIDES FOR COVALENT LABELING OF CORTICOTROPIN-RELEASING FACTOR (CRF) BINDING PROTEIN | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2002-11-28 | — | — | WO | disclosed |
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-4762881-A | Photoreactive benzoylphenylalanines and related peptides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | MDM4 2486/4885TP53 2793/4885PPARG 729/4885 |
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | CYP2E1, CYP1A1, CYP7A1 | MDM4 2296/4885TP53 2981/4885PPARG 404/4885 |
| US-11891655-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | CYP2E1, CYP1A1, CYP7A1 | MDM4 2296/4885TP53 2981/4885PPARG 404/4885 |
| US-20220282317-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | CYP2E1, CYP1A1, CYP7A1 | MDM4 2296/4885TP53 2981/4885PPARG 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.